Elanco Animal Health (NYSE:ELAN) Insider Purchases $94,272.84 in Stock

Elanco Animal Health Incorporated (NYSE:ELAN) insider Shiv O’neill bought 3,998 shares of Elanco Animal Health stock in a transaction dated Tuesday, August 18th. The stock was acquired at an average cost of $23.58 per share, for a total transaction of $94,272.84. Following the purchase, the insider directly owned 87,832 shares in the company, valued at approximately $2,071,078.56. The trade was a 4.77% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Elanco Animal Health Stock Down 4.2%

Shares of NYSE:ELAN opened at $23.47 on Friday. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10. The stock has a market cap of $11.73 billion, a price-to-earnings ratio of -57.24, a P/E/G ratio of 1.47 and a beta of 1.67. The company has a 50 day moving average of $24.56 and a 200-day moving average of $24.01. Elanco Animal Health Incorporated has a one year low of $17.11 and a one year high of $27.98.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. During the same period in the prior year, the business posted $0.26 earnings per share. Elanco Animal Health’s revenue was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, sell-side analysts forecast that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ELAN. Wall Street Zen cut Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. TD Cowen increased their target price on Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. JPMorgan Chase & Co. raised their target price on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Piper Sandler restated an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, June 29th. Finally, Morgan Stanley upped their price target on Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Elanco Animal Health has an average rating of “Moderate Buy” and an average target price of $29.09.

Institutional Trading of Elanco Animal Health

Hedge funds have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in shares of Elanco Animal Health in the second quarter valued at approximately $1,202,198,000. Primecap Management Co. CA acquired a new stake in shares of Elanco Animal Health during the second quarter worth $1,118,402,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Elanco Animal Health during the second quarter worth $205,636,000. UBS Group AG raised its holdings in shares of Elanco Animal Health by 56.7% during the third quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock worth $331,669,000 after acquiring an additional 5,961,457 shares during the period. Finally, Sei Investments Co. lifted its position in Elanco Animal Health by 737.5% in the 1st quarter. Sei Investments Co. now owns 5,650,393 shares of the company’s stock valued at $135,214,000 after acquiring an additional 4,975,721 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.